Back to search

Altx Therapeutics Limited

16677457

active
Private Limited Company
england wales
Companies House
Health Score
70 / 100

Some Concerns

30/30
Filing
0/30
Financial
40/40
Risk
  • Current liabilities exceed current assets (-10)
  • Going concern doubt noted in accounts (-10)

Details

BURNHAM HOUSE, SPLASH LANE, HUNTINGDON, PE28 2AF
Incorporated 28/08/2025

Compliance

Last accounts

31/03/2026

small

Next accounts due

31/12/2027

On track

Confirmation statement

Last:

Due 10/09/2026

On track

Industry

72110
Research and experimental development on biotechnology

Officers

Dr Gonzalo Andres Garcia Gajardo

director · Since 28/08/2025

DIRECTOR

BRITISH,CHILEAN · ENGLAND · Age 37

Also on 3 other boards

Mr Edward Eliot Hodgkin

director · Since 28/08/2025

MANAGING PARTNER

BRITISH · UNITED KINGDOM · Age 63

Also on 3 other boards

Archangel Accounting Limited

secretary · Since 20/10/2025

Also on 4 other boards

Dr David George Allen

director · Since 04/11/2025

BRITISH · UNITED KINGDOM · Age 67

Dr Simon Joseph Boulton

director · Since 04/11/2025

BRITISH · UNITED KINGDOM · Age 54

Persons with Significant Control

Slingshot Therapeutics Holdings Limited

50–75% shares
50–75% votes
Appoint directors

Burnham House, Splash Lane, Wyton, Huntingdon, PE28 2AF

Reg: 15871470 · Companies House · Private Limited Company

Notified 04/11/2025

Former PSCs

Slingshot Therapeutics Holdings Limited

Ceased 20/10/2025

Dr Simon Boulton

Ceased 04/11/2025

CompanyRankvs 1491+ SIC 72110 peers
43

Financial strength40th percentile among SIC peers · 10/25
Employees47th percentile among SIC peers · 7/15
LiquidityCurrent ratio 5.07× · 20/20
Longevity1 year trading (max 15) · 1/15
Filing complianceAll filings up to date · 15/15
Going concern doubt -10
Show leaderboard
How is this score calculated?
Financial strength10/25 pts

Net worth compared to all companies in the same SIC code with published accounts. Top quartile earns the full 25 points.

Employees7/15 pts

Workforce size relative to sector peers from the most recent accounts. A larger team generally signals commercial scale.

Liquidity20/20 pts

Current assets ÷ current liabilities. A ratio above 2× earns full marks; between 1–2× scores partially; below 0.5× scores minimal points.

Longevity1/15 pts

One point per year of operation since incorporation, capped at 15. Older companies have a proven track record.

Filing compliance15/15 pts

Full 15 points when both annual accounts and confirmation statement are filed on time. Points are deducted for each overdue filing.

Risk deductions

Going concern doubt: -10 pts

Maximum score is 100. Deductions apply for insolvency history, outstanding charges, going concern doubt, or disqualified officers.

Going Concern Doubt

of the second funding tranche represents a material uncertainty related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. ALTX THERAPEUTICS LIMITED NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE PERIOD ENDED 31 MARCH 2026 1 Accounting policies (Continued) - 3 - 1.3 Significant judgements and estimations In the a

Key FinancialsYear ending 31/03/2026

Net Worth

£70

Balance sheet strength

Cash

£3.6M

Cash in the bank

Net Current Assets

£3.1M

Working capital

Current Assets

£3.8M

Current Liabilities

£757k

Fixed Assets

£860

Debtors

£204k

1avg. employees

Balance Sheet

Assets less current liabilities£3.1M
Prepared with CCH Software

EstimatesDerived

YearCurrent Ratio
20265.07

Derived from filed accounts. Not audited figures.